Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.56 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.56 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.56 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.56 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24480430 | 0.98 | HPGD (0.58) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL17546310 | 0.92 | HPGD (0.52) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL21087637 | 0.92 | HPGD (0.63) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL13783342 | 0.91 | ALDH1A1 (0.61) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL13301267 | 0.91 | ALDH1A1 (0.68) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL10726764 | 0.91 | ALDH1A1 (0.60) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL2736674 | 0.89 | ALDH1A1 (0.72) | HPGDALDH1A1TSHRKMT2AMEN1 | |
| SCHEMBL8004911 | 0.88 | LMNA (0.52) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL26691473 | 0.87 | HPGD (0.47) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL13745751 | 0.87 | HTT (0.55) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3930838-B1 | N-(PYRIDINYL)ACETAMIDE DERIVATIVES AS P300/CBP HAT INHIBITORS AND METHODS FOR THEIR USE | CONSTELLATION PHARMACEUTICALS INC (US) | 2024-07-10 | — | — | EP | disclosed |
| WO-2023220247-A1 | LRRK2 INHIBITORS | INTERLINE THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| EP-3436461-B1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORP (US) | 2023-11-01 | — | — | EP | disclosed |
| CN-115093400-B | AhR inhibitor, application and preparation method thereof | 北京华森英诺生物科技有限公司 | 2023-09-05 | — | — | CN | disclosed |
| CN-114835687-B | AhR inhibitors | 北京华森英诺生物科技有限公司 | 2023-09-05 | — | — | CN | disclosed |
| EP-3722298-B1 | PYRROLO(PYRAZOLO)PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR | OSCOTEC INC (KR) | 2023-08-02 | — | — | EP | disclosed |
| EP-3558309-B1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | UNIV VANDERBILT (US) | 2023-07-26 | — | — | EP | disclosed |
| WO-2023125737-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF | SILEXON AI TECHNOLOGY CO., LTD. (CN) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023014908-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | Pipeline Therapeutics, Inc. (US) | 2023-02-09 | — | — | WO | disclosed |
| WO-2021122415-A9 | FUROINDAZOLE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2022-06-30 | — | — | WO | disclosed |
| US-20130165438-A1 | PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2013-06-27 | — | — | US | disclosed |
| US-8293736-B2 | Purine compounds selective for PI3K P110 delta, and methods of use | F. HOFFMANN LA ROCHE AG (CH) | 2012-10-23 | — | — | US | disclosed |
| WO-2012033069-A1 | PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS | 大鵬薬品工業株式会社 (JP) | 2012-03-15 | — | — | WO | disclosed |
| US-20120015931-A1 | PURINE COMPOUNDS SELECTIVE FOR PI3K P110 DELTA, AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | US | disclosed |
| EP-2374791-A1 | Insecticidal 4-phenyl-1H pyrazoles | Bayer CropScience Aktiengesellschaft (DE) | 2011-10-12 | — | — | EP | disclosed |
| US-20110190365-A1 | Insecticidal 4-phenyl-1H-pyrazoles | BAYER CROP SCIENCE AG (DE) | 2011-08-04 | — | — | US | disclosed |
| US-20110190365-A1 | Insecticidal 4-phenyl-1H-pyrazoles | BAYER CROP SCIENCE AG (DE) | 2011-08-04 | — | — | US | disclosed |
| WO-2011019060-A1 | HEDGEHOG SIGNAL INHIBITOR | 協和発酵キリン株式会社 (JP) | 2011-02-17 | — | — | WO | disclosed |
| US-7557113-B2 | Substituted pyrrolo[3,2-d]pyrimidine derivatives | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| US-7557113-B2 | Substituted pyrrolo[3,2-d]pyrimidine derivatives | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190365-A1 | Insecticidal 4-phenyl-1H-pyrazoles | CYP4X1, CYP4B1, CYP3A4 | HPGD 1575/4885CHRNB2 1698/4885CHRNA3 486/4885 |
| US-20130165438-A1 | PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS | PTGIS, PTGS1, PTGDR | HPGD 11/4885CHRNB2 1846/4885CHRNA3 1903/4885 |
| US-20120015931-A1 | PURINE COMPOUNDS SELECTIVE FOR PI3K P110 DELTA, AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CG | HPGD 3933/4885CHRNB2 1834/4885CHRNA3 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.